Program
elinzanetant
Also written as “Elinzanetant (BAY3427080)”, “GSK1144814” and “BAY3427080”.
Its studies are mostly in Hot Flashes · Schizophrenia, led by 2 companies.
Drug pageElinzanetant: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 212 open or running | phase 3since Aug 26, 2021 | Aug 3, 2016 | Jan 22, 2027phase 1 · NCT07762287 |
| GlaxoSmithKline | 30 open or running | phase 1since Mar 4, 2010 | Mar 4, 2010 | none ahead |
Also a collaborator on its studies: Nerre Therapeutics and Quotient Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GlaxoSmithKline only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Mar 4, 2010First study: phase 1 study in SchizophreniaFirst studyNCT01090440 · 16 enrolled · Australia
- Aug 30, 2010Phase 1 study in SchizophreniaNCT01209039 · 41 enrolled · United Kingdom
- Jun 9, 2011Phase 1 study in SchizophreniaNCT01381419 · 21 enrolled · United Kingdom
- Dec 9, 2019Named elinzanetantINNProposed as its International Nonproprietary Name in WHO's List 122 · before, GSK1144814, BAY3427080
TargetBeta
“An orally bioavailable neurokinin/tachykinin 1 receptor (NK1-receptor; NK1R; NK-1R) and NK3 receptor (NK-3R; NK3R) antagonist, that may be used to treat vasomotor symptoms in menopausal woman”NCIt, by rule
“Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist”ChEMBL 37, by rule
Studies
All 3 GlaxoSmithKline leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01381419Schizophrenia · United Kingdom | 1 | Completed | Apr 1, 2009 | 21 |
| NCT01209039Schizophrenia · United Kingdom | 1 | Completed | Oct 25, 2009 | 41 |
| NCT01090440Schizophrenia · Australia | 1 | Completed | Oct 9, 2009 | 16 |
How it is read
Names in the registry
- “Elinzanetant (BAY3427080)”, 15 entries
- “GSK1144814”, 7 entries
- “BAY3427080”, 2 entries
- “Elinzanetant (BAY 3427080) treatment A”, 1 entry
- “Elinzanetant (BAY 3427080) treatment B”, 1 entry
Conditions, from the studies’ own filings
- Hot Flashes, 13 studies
- Schizophrenia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.